ライフサイエンスコーパス: major depression

1 with the susceptibility to schizophrenia or major depression.

2 tes, is associated with an increased risk of major depression.

3 or no meaningful benefit in outpatients with major depression.

4 brain bioenergetic function in subjects with major depression.

5 striatal dopaminergic indices in suicide and major depression.

6 represent the majority of those affected by major depression.

7 ission with venlafaxine in older adults with major depression.

8 lar disorder, and class III was increased in major depression.

9 predictors in treatment-naive patients with major depression.

10 anial direct current stimulation (tDCS), for major depression.

11 ailure with first-line treatment options for major depression.

12 nd parietal regions were more substantial in major depression.

13 mental role for NRG3 in bipolar disorder and major depression.

14 al and emotional impact of RPEs is intact in major depression.

15 ion is supposed to be a pathogenic factor in major depression.

16 ted with schizophrenia, bipolar disorder and major depression.

17 depressive symptoms, even in the absence of major depression.

18 ccelerated aging molecular profiles, such as major depression.

19 en severe, can appear indistinguishable from major depression.

20 th psoriasis met criteria for a diagnosis of major depression.

21 nonsignificant reduction in the incidence of major depression.

22 the frontal pole as particularly altered in major depression.

23 lving brain networks known to be affected by major depression.

24 ty of psoriasis was unrelated to the risk of major depression.

25 , regardless of severity, may be at risk for major depression.

26 onment) had a significantly reduced risk for major depression.

27 it neurobiological underpinnings of risk for major depression.

28 ction in women with antidepressant-resistant major depression.

29 dically stable, unmedicated outpatients with major depression.

30 bit antidepressant activity in patients with major depression.

31 ve disorders including anxiety disorders and major depression.

32 en severe, can appear indistinguishable from major depression.

33 or only a small portion of burden related to major depression.

34 ificantly reduced in patients with psychotic major depression.

35 Randomization stratified for comorbid major depression.

36 DA) receptor antagonists in the treatment of major depression.

37 luence of the amygdala in chronic stress and major depression.

38 antidepressant effect in treatment-resistant major depression.

39 lts about its influence on disorders such as major depression.

40 ty and negative mood states in patients with major depression.

41 n, ages 21-70, with antidepressant-resistant major depression.

42 and structure may be a target biomarker for major depression.

43 bcortical increments in schizophrenia versus major depression.

44 across sexes in their impact on liability to major depression.

45 (VBM) and functional (VBP) abnormalities in major depression.

46 PHQ-9 scores >=10, suggesting a diagnosis of major depression.

47 he search for novel effective treatments for major depression.

48 relevant to its therapeutic use for treating major depression.

49 le of rearing environment in the etiology of major depression.

50 isk for schizophrenia, bipolar disorder, and major depression.

51 ing posttraumatic stress disorder (PTSD) and major depression.

52 risk factor for the onset and recurrence of major depression.

53 havior therapy is an effective treatment for major depression.

54 and acceptability in the acute treatment of major depression.

55 ral basis of psychiatric conditions, such as major depression.

56 ible studies (44 318 participants; 4572 with major depression [10%]; mean [SD] age, 49 [17] years; 59

57 zophrenia: 29%) than first-episode patients (major depression: 15%; schizophrenia: 12%).

58 of an anxiety disorder (2.27, 1.2-4.28), and major depression (2.23, 1.24-4.01).

59 patients had higher misclassification rates (major depression: 23%; schizophrenia: 29%) than first-ep

60 cant variants for schizophrenia, 5 of 40 for major depression, 3 of 11 for ADHD and 1 of 2 for autism

61 6.2% (95% CI 4.0-8.6), 16.0% (11.7-20.8) for major depression, 3.8% (1.2-7.6) for alcohol use disorde

62 yzed data from 80 older adults with remitted major depression (36 with mild cognitive impairment (LLD

63 cipants in the GSP group were diagnosed with major depression 6 months post-treatment compared with 1

64 ed to identify white matter abnormalities in major depression (736 patients vs. 668 control subjects)

65 s have demonstrated HPA axis overactivity in major depression, a relationship of HPA axis activity to

66 ationship between childhood maltreatment and major depression according to 5-HTTLPR genotype.

67 e established evidence for Hb involvement in major depression, addiction, and schizophrenia, as well

68 139 outpatients with persistent symptoms of major depression after an 8-week open-label trial of esc

69 They often co-occur with major depression, alcohol and other substance-use disord

70 four major psychiatric diagnoses: psychosis, major depression, alcohol use disorders, and drug use di

71 ) cases of psoriasis and 968 (7.8%) cases of major depression among 12,382 US citizens included in ou

72 In all, 32 patients with TRD (17 with major depression and 15 with bipolar depression) who res

73 l cortical regions in 2,256 individuals with major depression and 3,504 control subjects from 31 sepa

74 Eighty medication-free outpatients with major depression and 34 matched healthy controls were in

75 ortical structures in 2,540 individuals with major depression and 4,230 control subjects from 32 data

76 utamatergic system in the pathophysiology of major depression and also as a target for rapid-acting a

77 Major depression and anxiety disorders are a social and

78 Major depression and anxiety disorders are treated using

79 ern, seen in the internalizing conditions of major depression and anxiety disorders, risk was associa

80 e of these neurons as therapeutic targets in major depression and anxiety disorders.

81 a risk factor for mental disorders, such as major depression and anxiety.

82 to schizophrenia, autism, bipolar disorder, major depression and attention deficit hyperactivity dis

83 Major depression and bipolar disorder are characterized

84 ructure differences and similarities between major depression and bipolar disorder is a necessary ste

85 an important player in the neurochemistry of major depression and bipolar disorder.

86 served sex differences in the comorbidity of major depression and cardiovascular disease.

87 ity to a range of brain disorders, including major depression and cognitive deficits.

88 74 older individuals (age >/= 65 years) with major depression and cognitive impairment to the level o

89 Identifying risk factors for major depression and depressive symptoms in youths could

90 to address the unmet needs of patients with major depression and even shorter life expectancy.

91 scitalopram and duloxetine) in patients with major depression and examined the moderating effect of p

92 sample of 221 adults 60 years and older with major depression and executive dysfunction were randomiz

93 mes were the proportion of participants with major depression and function scores at 6 months post-tr

94 The only notable small difference was that major depression and generalized anxiety disorder dimens

95 ially involved in its therapeutic effects on major depression and generalized anxiety disorder.

96 subcortical volume between individuals with major depression and healthy control subjects.

97 ve psychosis was on average 16 times higher, major depression and illicit drug use disorder prevalenc

98 ); (4) severe psychiatric disease (including major depression and other major psychiatric diagnosis);

99 evelopment of new therapeutic strategies for major depression and other mood disorders.

100 ystem in neuropsychiatric disorders, such as major depression and Parkinson's disease is enabled.

101 risk for neuropsychiatric disorders such as major depression and post-traumatic stress disorder.

102 tial therapeutic target for the treatment of major depression and postpartum mood disorders.

103 development of affective disorders including major depression and posttraumatic stress disorder.

104 ns of hippocampal and amygdala structures in major depression and predictors of ECT-related clinical

105 od maltreatment to modulate vulnerability to major depression and PTSD and epigenetic mechanisms thou

106 nd, phase 2 trial, we enrolled patients with major depression and randomly assigned them in a 1:1 rat

107 Many neurological diseases including major depression and schizophrenia manifest as dysfuncti

108 tify key priorities for future research into major depression and schizophrenia, including studies of

109 was correct in 80% and 72% of patients with major depression and schizophrenia, respectively, and in

110 luence psychiatric symptomatology, including major depression and schizophrenia.

111 contributing to the comorbidity of CAD with major depression and schizophrenia.

112 mpact on the neuroanatomical separability of major depression and schizophrenia.

113 been established as a major risk factor for major depression and suicidal behavior along with other

114 DNF), a key player in the pathophysiology of major depression and the action of antidepressants, in t

115 on (suggestive of schizophrenia, bipolar, or major depression) and treatment course (no treatment, tr

116 in 39 healthy participants, 39 patients with major depression, and 22 patients with major depression

117 including bipolar disease, schizophrenia and major depression, and a haplotype located in an intronic

118 r mental disorders, including schizophrenia, major depression, and bipolar disorders.

119 nduct disorder, drug abuse, prior history of major depression, and distal and dependent proximal stre

120 apping genetic architectures (schizophrenia, major depression, and educational attainment), we identi

121 nfection and interferon-alpha, patients with major depression, and healthy controls).

122 women, with symptoms similar to anxiety and major depression, and is associated with differential se

123 ression significantly prevented the onset of major depression, and maintenance IPT significantly redu

124 Recent failed clinical trials of DBS in major depression, and modest treatment outcomes in demen

125 432 subjects PRS scores for plasma cortisol, major depression, and neuroticism were calculated using

126 re that overlaps with that of schizophrenia, major depression, and other disorders.

127 equelae (APNS) such as posttraumatic stress, major depression, and regional or widespread chronic mus

128 een adoption status and depressive symptoms, major depression, and schizophrenia were observed.

129 ssociation between a stress-related disease, major depression, and the amount of mtDNA (p = 9.00 x 10

130 ironment has a meaningful impact on risk for major depression, and this effect is likely mediated bot

131 ving away from traditional blinded trials in major depression, and whether preclinical models tell us

132 the decision processes that are impacted in major depression, and whose further study could lead to

133 ia associated with autoimmune diseases, with major depression, and with unexplained chronic fatigue.

134 Thus, more effective treatments for major depression are needed, and targeting certain hormo

135 e results suggest that important features of major depression are not captured by DSM criteria.

136 Patients with major depression are prone to several comorbid psychiatr

137 psoriasis was independently associated with major depression as assessed by a validated screening to

138 found, a simple family history assessment of major depression as part of clinical care can be a predi

139 ed 19 years and older, with mild to moderate major depression assessed with the Mini International Ne

140 New cases of major depression, assessed every 6 months for 18 months.

141 n of parents who had documented histories of major depression (at-risk, n = 27; 8-14 years of age) an

142 Diagnosis of major depression based on the Patient Health Questionnai

143 treated hypothyroidism, Addison syndrome and major depression before treatment.

144 icable neuroimaging features associated with major depression, beyond the transdiagnostic effects rep

145 Polygenic risk scores (PRSs) for major depression, bipolar disorder, and schizophrenia we

146 ase in risk for major psychiatric disorders (major depression, bipolar disorder, post-traumatic stres

147 d past diagnoses of self-inflicted injuries, major depression, bipolar disorder, substance use disord

148 luding healthy controls and individuals with major depression, bipolar psychosis and schizophrenia we

149 ms in schizophrenia or psychotic symptoms in major depression, but earlier disease onset and accelera

150 r antidepressant medication for nonpsychotic major depression can be extended to treatment-naive pati

151 ines how well DSM-5 symptomatic criteria for major depression capture the descriptions of clinical de

152 (PATH) is a treatment for older adults with major depression, cognitive impairment (from mild cognit

153 ion group (95% CI, 5.85% to 8.95%) developed major depression compared with 9.40% in the control (usu

154 ched full and half sibships at high risk for major depression, compared with individuals raised in th

155 sion in 143 older outpatients diagnosed with major depression comparing treatment response in three t

156 ric Genomics Consortium (PGC), the PGC2-MDD (Major Depression Dataset).

157 d to assess depressive symptoms and probable major depression (defined as Patient Health Questionnair

158 iority of behavioural activation therapy for major depression delivered via telemedicine to same-room

159 rter telomeres were seen in individuals with major depression, depressive disorders, and anxiety diso

160 me-wide genotyped and completed measures for major depression, depressive symptoms, and/or childhood

161 sis of studies that compared PHQ scores with major depression diagnoses, the combination of PHQ-2 (wi

162 The largest effect size (Cohen's d) of major depression diagnosis was 0.085 for the thickness a

163 psychiatry: Congestive Heart Failure (CHF), Major Depression Disorder (MDD), Parkinson's Disease (PD

164 correlated with depressive symptoms both in major depression disorder patients and healthy individua

165 data set of chronic variable stress mice and major depression disorder subjects showed that the chang

166 seases, such as autism spectrum disorder and major depression, drawing upon findings from animal mode

167 d brain ageing promoted misclassification in major depression due to an increased neuroanatomical sch

168 -2.79; P < .001), and receiving a diagnosis (major depression/dysthymia: OR, 2.65; 95% CI, 2.20-3.20

169 generalized anxiety disorder, social phobia, major depression, dysthymic disorder, and/or minor depre

170 t, in part because the clinical diagnosis of major depression encompasses biologically heterogeneous

171 stionnaire in 331 employed participants with major depression enrolled in the Combining Medications t

172 to identify molecular mechanisms relevant to major depression, especially in the context of enhanced

173 ical asymmetry may be of little relevance to major depression etiology in most cases.

174 Psoriasis was significantly associated with major depression, even after adjustment for sex, age, ra

175 nalytic approach to test the hypothesis that major depression exhibits spatially convergent structura

176 While numerous treatments for major depression exist, many patients do not respond ade

177 asidone in adults with nonpsychotic unipolar major depression experiencing persistent symptoms after

178 diovascular event did not modify the risk of major depression for patients with psoriasis.

179 onal Neuropsychiatric Interview criteria for major depression from an urban HIV care centre in Kitgum

180 an overview of our current understanding of major depression, from pathophysiology to treatment.

181 Standardised scales measured major depression, generalised anxiety, alcohol misuse, a

182 m disorder, schizophrenia, bipolar disorder, major depression, generalized anxiety disorder, agorapho

183 t and youth informants for conduct disorder, major depression, generalized anxiety disorder, separati

184 nt and youth informants for conduct disorder,major depression, generalized anxiety disorder, separati

185 assigned 74% of the bipolar patients to the major depression group, while 83% of the first-episode p

186 who were 60 years of age or older and whose major depression had failed to remit with venlafaxine hy

187 es, research in the biology and treatment of major depression has led to advances in our understandin

188 Generalized anxiety and major depression have become increasingly common in the

189 Neuroimaging studies of patients with major depression have revealed abnormal intrinsic functi

190 cortex (OCC) in 13 subjects with T1D without major depression (HbA(1c) 7.1 +/- 0.7% [54 +/- 7 mmol/mo

191 standing of distorted cognitive processes in major depression; however, this model's conception of co

192 ment of adults (aged 18 years or older) with major depression, identified from the Cochrane Central R

193 ation antidepressants for acute treatment of major depression in adults (update: Jan 8, 2016).

194 adolescence is the major period of onset for major depression in both risk groups, it is the offsprin

195 oducible association of the SIRT1 locus with major depression in humans.

196 Major depression in older adults is common and can be ef

197 The increased rates of major depression in the high-risk group were largely acc

198 ession in the nonshared parent, the risk for major depression in the matched adopted compared with ho

199 at birth, and, for half siblings, history of major depression in the nonshared parent, the risk for m

200 The increased risk of major depression in the offspring of depressed parents i

201 stpartum period appears to heighten risk for major depression in women.

202 onsortium genome-wide association studies of major depression (including data from 23andMe) and bipol

203 Despite a broad armamentarium for major depression, including antidepressants, evidence-ba

204 The absolute prevalence of probable major depression increased by 7% after Occupy Central, r

205 and demonstrates that genetic liability for major depression increases risk for suicide attempt acro

206 identified for risky behaviour (excitatory), major depression (inhibitory), schizophrenia (excitatory

207 site-specific permuted blocks stratified by major depression into groups prescribed CIT (n = 101), p

208 Major depression is a debilitating psychiatric illness t

209 ne system dysfunction in the pathogenesis of major depression is also being intensively investigated.

210 igated whether a polygenic susceptibility to major depression is associated with response to lithium

211 Increasing clinical reports show that major depression is characterized by pronounced olfactor

212 Treatment-resistant major depression is common and potentially life-threaten

213 elivered psychotherapy for older adults with major depression is not inferior to same-room treatment.

214 with increased glutamate among patients with major depression is unknown.

215 ult participants with a current diagnosis of major depression (LLD) from the Alzheimer's Disease Neur

216 al regions of the uncinate circuit, and that major depression may accentuate age-related attenuation

217 Moreover, patients with comorbid major depression may fare better with IPT than with prol

218 data indicate that increased inflammation in major depression may lead to increased glutamate in the

219 oups: schizophrenia, bipolar disorder (BPD), major depression (MD) and unaffected controls.

220 Alcohol dependence (AD) and major depression (MD) are leading causes of disability t

221 ed polygenic scores (PGSs) were computed for major depression (MD) at different GWAS p value threshol

222 Major depression (MD) is determined by a multitude of fa

223 schizophrenia (SCZ), bipolar disorder (BIP), major depression (MD), attention-deficit hyperactivity d

224 Past-year major depression (MD), generalized anxiety disorder (GAD

225 p are the historical roots of our concept of major depression (MD)?

226 The degree to which major depression (MDD) and bipolar disorder (BD) are ass

227 capsule/ventral striatum (VCVS) DBS in both major depression (MDD) and obsessive-compulsive disorder

228 gnosed with type 2 diabetes with and without major depression (MDD), a healthy control group, and a g

229 and was positively associated with past-year major depression (mean [SE], 100 [0.5]; P = .01).

230 he clinical cohort comprised 279 youths with major depression (mean age=14.76 years [SD=2.00], 68% fe

231 cortical regions previously associated with major depression measured through T1-weighted magnetic r

232 f schizophrenia (n = 158) from patients with major depression (n = 104); and (ii) quantify the impact

233 ecutively recruited adults (>=60 years) with major depression (n = 249) were randomly assigned to 9 w

234 la structures were examined in patients with major depression (N = 43, scanned three times: prior to

235 inded, noninferiority trial of patients with major depression (N=138; 63% female; age=56.7 years [SD=

236 e diagnostic groups (healthy controls, n=17; major depression, n=38; and post-traumatic stress disord

237 dolescents (79% of those with a diagnosis of major depression; n = 023); most received psychotherapy

238 major depression (PMD) and with nonpsychotic major depression (NPMD) and healthy controls (HC) were s

239 Comorbid major depression occurred in 36.7% (95% CI, 6.2%-67.2%)

240 Major depression occurs in 2% of adults aged 55 years or

241 r significant after controlling for maternal major depression (odds ratio (OR) 1.10 (0.70-1.70)).

242 vivors and examined whether they experienced major depression or anxiety disorders during that year a

243 Health Questionnaire-9) and met criteria for major depression or dysthymia.

244 effect disappeared if an adoptive parent had major depression or if the adoptive home experienced par

245 of which are covered by the DSM criteria for major depression or melancholia.

246 domestic violence, and those diagnosed with major depression or psychotic disorders were excluded.

247 whether these findings reflect the state of major depression or reflect trait neurobiological underp

248 d when an adoptive parent or stepsibling had major depression or the adoptive home was disrupted by p

249 Many older adults with major depression, particularly veterans, do not have acc

250 ) versus lateral (cognitive) frontal pole to major depression pathogenesis is currently unclear.

251 functionally connect to other key regions in major depression pathology, such as the anterior cingula

252 atients with major depression with psychotic major depression (PMD) and with nonpsychotic major depre

253 tom of most psychiatric disorders, including major depression, post-traumatic stress disorder, schizo

254 r understanding of the circuitry involved in major depression, providing potential new therapeutic ta

255 t reveal a synergistically increased risk of major depression (psoriasis and MI: OR, 1.09 [95% CI, 0.

256 enotypes, measured with childhood trauma and major depression questionnaires, to epigenetically up-re

257 ate-to-severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (

258 Community adults with major depression, recurrent with seasonal pattern (N=177

259 ion, and decreased function in patients with major depression relative to healthy control subjects.

260 atients with bipolar disorder have recurrent major depression, residual mood symptoms, and limited tr

261 People with major depression, schizophrenia, and Parkinson's disease

262 udes randomized controlled trials of tCS for major depression, schizophrenia, cognitive disorders, an

263 ne (score <16), minor (score 16 to <21), and major depression (score>/=21); and Center for Epidemiolo

264 Hospital Anxiety and Depression Scale; then, major depression section of the Structured Clinical Inte

265 The early onset of major depression seen in the offspring of depressed pare

266 Patients with major depression show reductions in striatal and paleost

267 Major depression shows distinct response trajectories to

268 ficit/hyperactivity disorder, schizophrenia, major depression, smoking, personality, cognition and bo

269 status based on severity cutoff scores, and major depression status from tracking calls.

270 red in January or February of each year, and major depression status was assessed by telephone in Oct

271 with bipolar II disorder; one patient in the major depression subgroup was later reclassified as havi

272 hysiology of psychiatric diseases, including major depression, substance abuse, and schizophrenia.

273 th major depression were at highest risk for major depression, suggesting the potential value of dete

274 Psychiatric Genomics Consortium analysis of major depression than from that for bipolar disorder rea

275 ts were 177 adults with a current episode of major depression that was recurrent with a seasonal patt

276 s having at least one biological parent with major depression, the authors identified a Swedish Natio

277 For major depression, the most prevalent psychiatric disorde

278 he genomics of the response of patients with major depression to cognitive behavior therapy were comp

279 dala reactivity is observed in patients with major depression, two critical gaps in our knowledge rem

280 rize response trajectories for patients with major depression undergoing left dorsolateral prefrontal

281 evaluate if AC3 is a contributing factor for major depression using mouse models lacking the Adcy3 ge

282 The risk for major depression was approximately three times as high i

283 Major depression was assessed from national medical regi

284 Polygenic risk score for major depression was associated specifically with increa

285 n adjusted multivariable models, the risk of major depression was not significantly different between

286 ng with 2 previous generations affected with major depression were at highest risk for major depressi

287 cores (PRS) for BD, schizophrenia (SCZ), and major depression were calculated and compared between th

288 f Chinese adults older than 60 years who had major depression were improved when their primary care c

289 Patients with comorbid major depression were nine times more likely than nondep

290 THOD: Adults aged 18-65 with treatment-naive major depression were randomly assigned with equal likel

291 Polygenic risk scores for major depression were significantly associated with suic

292 on design study was conducted in adults with major depression who had an inadequate response to one o

293 Previously untreated adults with major depression who were randomly assigned to receive e

294 d Health Organization projects that by 2030, major depression will be the leading cause of disease bu

295 but not unipolar major depressive disorder (major depression with no bipolarity; 18.9% compared with

296 bgenual cortex is disrupted in patients with major depression with psychotic features.

297 Patients with major depression with psychotic major depression (PMD) a

298 would be most apparent in patients that have major depression with psychotic symptoms, who typically

299 with major depression, and 22 patients with major depression with psychotic symptoms.

300 s monotherapies or adjunctive treatments for major depression, with therapeutic actions attributable